We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Demonstrates the Viability of Coronary Artery Calcification Testing in Asymptomatic Patients

By HospiMedica International staff writers
Posted on 13 Jul 2015
The results of a cohort study that investigated the ability of Computed Tomography (CT) Coronary Artery Calcification (CAC) scores to predict mortality in people with no symptoms of coronary artery disease have been published.

The researchers, from Emory University School of Medicine (Atlanta, Georgia), Weill Cornell Medical College (New York, NY; USA), Johns Hopkins Ciccarone Center for the Prevention of Heart Disease (Baltimore, MD), Cedars-Sinai Medical Center (Cedars, USA‎), Harbor–UCLA Medical Center (Los Angeles, CA; USA), and Tennessee Heart and Vascular Institute (Hendersonville, TN, USA), published the results in the July, 7, 2015, issue of the Annals of Internal Medicine. More...
The researchers found a strong relation between near-term adverse clinical outcomes, and the CAC score, during a follow-up period of 15 years. The study group consisted of 9,715 asymptomatic patients. The researchers collected data about binary risk factors, coronary artery calcification, and mortality, and used uni- and multi-variable Cox proportional hazards models to compare the distribution of surviving study participants. The researchers also calculated the net reclassification improvement statistic.

The resulting Cox models, adjusted for risk factors for coronary artery disease, showed that the CAC score was highly predictive of all-cause mortality. Mortality rates during 15 years of follow up were 3% to 28% for CAC scores from 0 to 1,000 or higher, while the relative hazard for all-cause mortality ranged from 1.68 for a CAC score of 1 to 10, to 6.26 for a CAC score of 1,000 or more. The categorical net reclassification improvement score was 0.21.

The researchers concluded that the extent of CAC, in a large group of asymptomatic patients, could accurately predict their 15-year mortality. The study demonstrated that CAC and other biomarkers can be used to accurately predict patient outcomes.

Related Links:

Emory University School of Medicine
Weill Cornell Medical College
Cedars-Sinai Medical Center



New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Gas Analyzer
GE SAM
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.